On Friday, Capital One Financial Corp. (NYSE:COF)’s shares inclined 0.67% to $81.27.
Capital One Financial Corporation (COF) declared a quarterly dividend of $0.40 per share payable August 20, 2015 to stockholders of record as of August 10, 2015. The company has declared dividends on its common stock every quarter since it became an independent company on February 28, 1995. Dividends declared by the company are eligible for direct reinvestment in the company’s common stock under its Dividend Reinvestment and Stock Purchase Plan. For additional Plan information, stockholders should contact Computershare Trust Company, N.A., at 1-888-985-2057 (inside the U.S. and Canada) or 1-781-575-2725 (outside the U.S. and Canada).
Capital One Financial Corporation operates as the bank holding company for the Capital One Bank (USA), National Association (COBNA); and Capital One, National Association (CONA), which provide various financial products and services in the United States, the United Kingdom, and Canada. It operates through three segments: Credit Card, Consumer Banking, and Commercial Banking. The company offers various non-interest bearing and interest-bearing deposits, such as demand deposits, money market deposits, time deposits, negotiable order of withdrawal accounts, and savings accounts .
Principal Financial Group Inc (NYSE:PFG))’s shares gained 1.84% to $57.98.
Principal Financial Group, Inc. (PFG) declared results for second quarter 2015.
- Operating earnings raised to $323.9 million for second quarter 2015, contrast to $323.1 million for second quarter 2014. After adjusting for normalizing items and foreign exchange rates, operating earnings raised 10 percent over second quarter 2014. Operating earnings per diluted share (EPS) raised 1 percent to $1.09 for second quarter 2015, contrast to $1.08 for second quarter 2014.
- Net incomeaccessible to common stockholders for second quarter 2015 reduced to $241.1 million, or 81 cents per diluted share, contrast to $306.3 million, or $1.03 per diluted share for second quarter 2014.
- Operating revenuesraised 34 percent in second quarter 2015 to $3,406.8 million from higher sales and fee income, contrast to $2,542.6 million for second quarter 2014.
- Fee income3raised 6 percent to $908.5 million for the second quarter 2015, contrast to $855.3 million for second quarter 2014.
Principal Financial Group, Inc. provides retirement, asset administration, and insurance products and services. It operates through Retirement and Investor Services, Principal Global Investors, Principal International, and U.S. Insurance Solutions segments. The Retirement and Investor Services segment provides a portfolio of asset accumulation products and services for retirement savings and investment to businesses, institutional clients, and employees of business and other individuals.
At the end of Friday’s trade, Omeros Corporation (NASDAQ:OMER)‘s shares dipped -1.82% to $12.96.
Omeros Corporation (OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market in addition to orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, recently declared recent highlights and developments in addition to financial results for the second quarter of 2015, which comprise:
- Revenues of $3.2 million, $3.1 million of which resulted from net product sales of Omidria®(phenylephrine and ketorolac injection) 1% / 0.3% following its broad commercial U.S. launch in mid-April
- Net loss of $16.7 million, or $0.44 per share, which comprised of $2.7 million ($0.07 per share) of non-cash expenses for the three months ended June 30, 2015
- Omidria reimbursement has already been established from all Medicare Administrative Contractors across all states in the U.S. and Puerto Rico and from nearly all of the nation’s top 30 commercial payers and others, representing about 135 million insured lives
- Establishing Omidria financial assistance program for patients covered by government insurers and a copay program for those commercially insured – both programs are designed to expand access to Omidria to all U.S. cataract surgery patients
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets Omidria for use during cataract surgery or intraocular lens, or replacement surgery.
Pengrowth Energy Corp (USA) (NYSE:PGH), ended its Friday’s trading session with -4.62% loss, and closed at $1.24.
Pengrowth Energy Corporation (PGH) declared that its August 17, 2015 cash dividend will be Cdn $0.02 per common share. The ex-dividend date is July 20, 2015. The dividend will be payable to all shareholders who hold Pengrowth shares at the close of business on the record date of July 22, 2015.
The dividend of Cdn $0.02 per common share is equivalent to about U.S. $0.016 per common share using a Canadian/U.S. dollar exchange rate of Cdn $1.00:U.S. $0.786. The actual U.S. dollar equivalent of the dividend will be based upon the actual Canadian/U.S. dollar exchange rate in effect on the payment date, net of applicable Canadian withholding taxes for U.S. residents who hold their Pengrowth shares in taxable accounts.
Pengrowth Energy Corporation engages in the acquisition, development, exploration, and production of oil and natural gas assets in the Alberta, British Columbia, Saskatchewan, and Nova Scotia provinces in Canada. It primarily explores for crude oil, bitumen, natural gas, and natural gas liquids. The company’s assets comprise Cardium light oil, Lindbergh thermal, and Swan Hills light oil projects.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
